Equity
€2.5m ▲ 8.9%
ORTHOPATH has made a profit in every financial year since 2006.
ORTHOPATH
Lifetime
20 annual accounts with figures on one time axispeak €413,299 (2021)
€271,756▼ 28.1%
peak €276,243 (2021)
€202,527▼ 16.9%
peak €2.5m (2025)
€2.5m▲ 8.9%
€38,511▼ 5.3%
Board2 names since 2005
2 directors and 1 other
Documentsfilings and deeds
13-07-202618 days before the deadline
2025abbreviated format
Gross margin from €378,063 to €271,756
Key points
from the 2025 annual accountsTurnover
≈ €410,000 estimated
The accounts state no turnover.
Position in the sector
98.5%
Higher solvency than 95% of companies in human health. Sector median 59.4% · 2,809 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 20,135 companies had the same profile as ORTHOPATH has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,135 companies, not a prediction for ORTHOPATH. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 13-10-2005
Director, since 13-10-2005
- 50 sharesdeed of 31-10-2023
- 50 sharesdeed of 31-10-2023
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0876656009
Legal-form change · Resignations & appointments
Resignations: (director) and (director) · Appointments: (director) and (director) · holds 50 shares · General meeting of 23-10-2023 · Gazette deed
Capital decrease of €194,450 to €18,550
Capital from €213,000 to €18,550 · Reappointments: (manager) and (manager) · General meeting of 15-03-2018 · Gazette deed
Incorporation
published on 26-10-2005 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ORTHOPATH Brasschaat | €2.5m | €271,756 | 98.5% | - |
| Dokter Geert Peersman Schilde | €2.2m | €263,666 | 59.0% | - |
| CARDIOLOOG JAN VERCAMMEN Aalter | €2.4m | €277,994 | 81.4% | - |
| DAG-med Estinnes | €2.8m | €307,205 | 75.2% | - |
| Dr. WU Brasschaat | €2.0m | €226,692 | 89.5% | - |
| Klinisch bioloog Walter Verstrepen Kontich | €2.5m | €308,846 | 97.5% | - |
| DR. ROBERT VANDEURZEN Oud-Turnhout | €2.1m | €236,404 | 93.6% | - |
These companies have the same main activity as ORTHOPATH: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €2m and €2.8m, founded between 2004 and 2008.
Official details
Source: KBO- Status
- Active since 13-10-2005Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.273.624.5702930 Brasschaat, since 13-10-2005
- Financial year end
- 31 December
- Peppol
- Reachable since 03-11-2025
Annual accounts 2025
- €2.5m▲ 8.7%
- Filing
- Filed on 13-07-2026, 18 days before the end of the filing period
Insights on ORTHOPATH
ORTHOPATH files the abbreviated format. That format states no turnover. The gross margin fell from €289,941 in 2006 to €271,756 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ORTHOPATH
- What is the company number of ORTHOPATH?
- The company number of ORTHOPATH is 0876.656.009. The VAT number is the same number with BE in front: BE 0876.656.009.
- Where is ORTHOPATH based?
- The registered office is at Van Gamerenlei 17, 2930 Brasschaat.Company details
- What does ORTHOPATH do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of ORTHOPATH?
- ORTHOPATH is a private limited company (BV).
- When was ORTHOPATH founded?
- ORTHOPATH was founded on 13-10-2005.
- Is ORTHOPATH still active?
- Yes, ORTHOPATH is an active enterprise in the KBO register.
- What is the turnover of ORTHOPATH?
- The turnover in financial year 2025 is ≈ €410,000. This figure is estimated from the gross margin of €271,756 and 31 comparable companies (NACE 86220). It probably lies between €360,000 and €570,000.Financials
- Is ORTHOPATH profitable?
- In financial year 2025, ORTHOPATH made a profit of €202,527.
- Where can I find the annual accounts of ORTHOPATH?
- ORTHOPATH filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ORTHOPATH due?
- ORTHOPATH must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.